CBE and CBEC Supplements: Changes Being Effected Filing Guide

CBE and CBEC Supplements: Changes Being Effected Filing Guide

Key Takeaways

CBE Supplements: The Regulatory Mechanism

The Changes Being Effected (CBE) supplement mechanism exists because FDA recognized that requiring prior approval for every post-approval change would be impractical and unnecessary. Some changes present low or moderate risk to product quality and safety, and the public interest is better served by allowing implementation before full FDA review — provided the applicant accepts the risk that FDA may later disagree.

CBE supplements are not approvals. They are notifications. The applicant is informing FDA that a change has been made (CBE-0) or will be made in 30 days (CBE-30). FDA retains the authority to require the applicant to reverse the change, cease distribution, or submit a Prior Approval Supplement (PAS) instead.

This distinction matters. An applicant distributing product under a CBE supplement is doing so at its own risk. If FDA determines the change should have been filed as a PAS, the applicant may need to recall product, revert to the original process, and submit a new application.

CBE-0 vs. CBE-30: Regulatory Distinction

CBE-0 (Changes Being Effected at Implementation)

Regulatory basis: 21 CFR 314.70(d)

CBE-0 supplements permit the applicant to implement the change and distribute the product immediately upon submitting the supplement to FDA. There is no waiting period.

CBE-0 is reserved for changes with minimal potential to adversely affect the product. The regulation specifically identifies certain labeling changes as CBE-0-eligible, particularly those that add or strengthen safety-related information.

When CBE-0 is appropriate:

CBE-30 (Changes Being Effected in 30 Days)

Regulatory basis: 21 CFR 314.70(c)

CBE-30 supplements require the applicant to submit the supplement to FDA and wait at least 30 calendar days before distributing product made with the change. During the 30-day period, FDA may:

1. Allow the 30 days to expire without comment (implicit permission to proceed)
2. Inform the applicant that the supplement is not approvable and that a PAS is required
3. Request additional information before the change can be implemented

The 30-day clock begins on the date FDA receives the supplement, not the date the applicant mails it.

When CBE-30 is appropriate:

Filing Requirements for CBE Supplements

CBE-0 Content Requirements

A CBE-0 supplement must include:

1. Cover letter (Module 1.2): Clearly state that this is a CBE-0 supplement under 21 CFR 314.70(d). Describe the change being implemented.
2. Identification of the application: NDA or ANDA number, supplement number, product name, dosage form, and strength(s).
3. Description of the change: What is changing, from what state (approved), to what state (proposed). Be specific and reference the affected sections of the approved application.
4. Rationale and justification: Explain why the change qualifies for CBE-0 reporting. For labeling changes, reference the safety information that necessitates the change.
5. Updated labeling (if applicable): Redlined comparison showing the exact text changes, plus clean copy of updated labeling. For prescribing information changes, include the updated Highlights section and Full Prescribing Information. Labeling must be in Structured Product Labeling (SPL) format per 21 CFR 314.50(l).
6. eCTD formatting: Submit as a new sequence in the eCTD lifecycle. Submission type should be "supplement" with sub-type "CBE-0."

CBE-30 Content Requirements

A CBE-30 supplement requires more supporting data than a CBE-0. The submission must include:

1. Cover letter (Module 1.2): State this is a CBE-30 supplement under 21 CFR 314.70(c). Describe the change.
2. Identification and change description: Same as CBE-0 requirements.
3. Rationale and justification: Explain why the change qualifies for CBE-30 (moderate potential to adversely affect the product). Reference applicable SUPAC guidance and change level if applicable.
4. Supporting data: This is the critical difference from CBE-0. The applicant must provide data demonstrating that the change does not adversely affect product quality. Typical supporting data includes:

1. Updated Module 3 sections: Replace affected sections of the eCTD Quality module.
2. Updated Module 2.3 Quality Overall Summary: If the change is significant enough to warrant QOS updates, include revised sections.

Distribution Rules and Timing

CBE-0 Distribution Timeline

CBE-30 Distribution Timeline

Critical Rule: What "Distribution" Means

Under 21 CFR 314.70, the restriction on distribution applies to drug product made with the change. The applicant may:

• Manufacture product with the change before the 30-day period expires (for CBE-30)
• Build inventory using the changed process
• Ship product to distribution centers

However, the applicant may NOT release the product for sale or transfer to customers until the distribution restriction is satisfied. For CBE-30, this means the product cannot be released until the 30-day period has passed without FDA objection.

FDA Review and Potential Rejection

What Happens After Filing

FDA does not "approve" CBE supplements in the same way it approves PAS supplements. The review process differs:

For CBE-0 supplements:

• FDA reviews the supplement and may issue an Acknowledgment Letter
• If FDA determines the change should have been a PAS, FDA may order the applicant to cease distribution of product made with the change (21 CFR 314.70(d)(3))
• FDA may request additional information
• There is no formal approval action; the supplement is "received" rather than "approved"

For CBE-30 supplements:

• FDA reviews the supplement during the 30-day period
• If no objection within 30 days, the applicant may proceed
• FDA may issue a letter stating the supplement is "not approvable" or requesting reclassification as a PAS
• Even after the 30-day period passes, FDA retains the right to later determine the change requires a PAS

Risk of Rejection: Practical Implications

If FDA determines a CBE change should have been a PAS, the consequences can be significant:

Common CBE Changes in Practice

Manufacturing Site Changes via CBE-30

Manufacturing site changes are among the most common CBE-30 supplements. Under SUPAC-IR, a Level 2 site change (different facility, same equipment type, SOPs, and environmental controls) qualifies for CBE-30 reporting.

Required supporting data for a Level 2 site change (SUPAC-IR):

• Side-by-side comparison of equipment lists (old site vs. new site)
• Confirmation that the same standard operating procedures apply
• One batch of product manufactured at the new site with full release testing
• Dissolution testing (multi-point, per USP)
• One batch on accelerated stability (40C/75% RH) plus commitment to long-term stability
• Updated batch record with new site information

Specification Changes via CBE-30

Tightening specifications (making acceptance criteria more restrictive) is a CBE-30-eligible change because it improves product quality. Examples include:

• Reducing the upper limit for a specified impurity from NMT 0.5% to NMT 0.3%
• Narrowing dissolution acceptance criteria from Q = 75% in 45 min to Q = 80% in 30 min
• Tightening assay range from 90.0-110.0% to 95.0-105.0%

Note: Relaxing specifications (making criteria less restrictive) requires a PAS because it increases the risk of releasing substandard product.

Safety Labeling Changes via CBE-0

Section 505(o)(4) of the FD&C Act (as amended by FDAAA 2007) gives FDA authority to require labeling changes for safety reasons. Applicants may also proactively update safety labeling via CBE-0 when new safety information becomes available from:

• Post-marketing adverse event reports (FAERS data)
• Published literature
• Post-marketing required studies (PMR)
• Signal detection and evaluation
• Periodic safety reports

The CBE-0 mechanism for safety labeling ensures that critical safety information reaches healthcare providers and patients without delay. FDA's position is that waiting for prior approval of safety labeling updates is not in the public interest.

CBE Supplements for ANDAs

ANDA holders follow the same 21 CFR 314.70 framework as NDA holders, but with additional considerations:

1. Labeling changes must match the Reference Listed Drug (RLD): ANDA holders generally cannot make independent labeling changes. Safety labeling changes to the RLD trigger a requirement for the ANDA holder to update their labeling accordingly, typically via CBE-0.
2. Suitability petitions may be required: If an ANDA holder wants to make certain changes (e.g., dosage form, route of administration), they may need to file a suitability petition under 21 CFR 314.93 rather than a supplement.
3. SUPAC guidances apply equally: The same SUPAC change levels and reporting categories apply to ANDA products.

Best Practices for CBE Supplement Filing

Pre-Submission Assessment

1. Document the categorization rationale. Before filing, write an internal assessment explaining why the change qualifies for CBE-0 or CBE-30 rather than PAS. This document should reference specific regulatory provisions and applicable SUPAC guidance.
2. Consult SUPAC guidance explicitly. Do not rely on general 314.70 criteria alone when SUPAC guidance exists for the dosage form. The SUPAC change levels are more specific and FDA expects applicants to follow them.
3. Obtain internal quality approval. The decision to file a CBE supplement should go through the company's quality management system, including risk assessment of the consequences if FDA disagrees with the categorization.

Submission Quality

1. Include a clear, complete cover letter. State the reporting category, cite the regulatory basis, describe the change precisely, and identify all affected sections of the application.
2. Provide sufficient comparability data. Incomplete data is the most common reason FDA requests additional information or reclassifies a CBE-30 as a PAS.
3. Use correct eCTD lifecycle operations. Replace updated sections; do not append duplicates. Ensure document versioning is clear.
4. File one change per supplement when possible. Bundling unrelated changes complicates review and increases rejection risk.

Post-Filing Monitoring

1. Track the 30-day clock (CBE-30). Maintain a log of the submission date, FDA receipt date (from eSub acknowledgment), and the date distribution may begin.
2. Monitor FDA correspondence. Check the FDA ESG inbox and mail for any communication regarding the supplement.
3. Maintain production records. Document which batches were manufactured under the changed conditions and which were distributed before vs. after any FDA action.

Key Regulatory References

References